Top Markets
#1 Status Status +19.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +14.26%
#4 Ontology Gas Ontology Gas +12.27%
#5 DMT-NAT DMT-NAT +8.99%
#6 Nillion Nillion +7.04%
#7 Provenance Blockchain Provenance Blockchain +7.02%
#8 Janction Janction +6.49%
#9 Cap Cap +6.34%
#10 Bedrock Bedrock +5.75%
Coin of the day
Status Status
Ρυθμίσεις
Γλώσσα
Ελληνικά
Νόμισμα
USD
Θέμα
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Κατάταξη σε μετοχές #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Τιμή μετοχής
$0.1502
Τελευταίος συγχρονισμός: 2024-11-04
Κεφαλαιοποίηση
$6.43M
Αλλαγή (1 ημέρα)
-5.45%
Αλλαγή (1 έτος)
0.00%
Χώρα
US
Εμπόριο Renalytix Plc (RNLX)

Κατηγορία

Healthcare
Έσοδα για την Renalytix Plc (RNLX)
Έσοδα τον Sep 2024 TTM: $2.35M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Renalytix Plc, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $2.35M. Το 2023, η εταιρεία είχε έσοδα $3.40M αύξηση σε σχέση με τα έσοδα του έτους 2022, τα οποία ήταν $2.97M. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Renalytix Plc από 2018 έως 2026
Έσοδα στο τέλος κάθε έτους
Έτος Έσοδα Αλλαγή
2026 (TTM) $2.35M 2.75%
2024 $2.29M -32.74%
2023 $3.40M 14.58%
2022 $2.97M 99.20%
2021 $1.49M 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Έσοδα Διαφορά Εσόδων Χώρα
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 $20.24B 860,571.77%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 $160.46M 6,722.29%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 $14.37B 610,937.33%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 $1.43B 60,785.16%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US